# EDGAR Filing Document

**Accession Number:** 0001520262
**File Stem:** 0001193125-25-252207
**Filing Date:** 2025-10
**Character Count:** 43377
**Document Hash:** 182873e09c012dfd35a775c3fcd342fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-252207.hdr.sgml**: 20251028

**ACCESSION NUMBER**: 0001193125-25-252207

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 28

**CONFORMED PERIOD OF REPORT**: 20251028

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251028

**DATE AS OF CHANGE**: 20251028

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alkermes plc.
- **CENTRAL INDEX KEY:** 0001520262
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981007018
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35299
- **FILM NUMBER:** 251421260

**BUSINESS ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000
- **BUSINESS PHONE:** 00-353-1-772-8000

**MAIL ADDRESS:**
- **STREET 1:** CONNAUGHT HOUSE
- **STREET 2:** 1 BURLINGTON ROAD
- **CITY:** DUBLIN 4
- **STATE:** L2
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANTLER SCIENCE TWO PLC
- **DATE OF NAME CHANGE:** 20110804

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Antler Science Two Ltd
- **DATE OF NAME CHANGE:** 20110509

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** October 28, 2025

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Ireland | 001-35299 | 98-1007018 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
| Connaught House**,** 1 Burlington Road | Connaught House**,** 1 Burlington Road | Connaught House**,** 1 Burlington Road |
| Dublin 4**,** Ireland D04 C5Y6 | Dublin 4**,** Ireland D04 C5Y6 | Dublin 4**,** Ireland D04 C5Y6 |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) |

---

**Registrant's telephone number, including area code: +** 353**-**1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Title of each class** | &nbsp;&nbsp;**Trading Symbol(s)** | &nbsp;&nbsp;**Name of each exchange on which registered** |
| &nbsp;&nbsp;Ordinary shares, $0.01 par value | &nbsp;&nbsp;ALKS | &nbsp;&nbsp;Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.** 

On October 28, 2025, Alkermes plc (the "Company") announced financial results for the three and nine months ended September 30, 2025 and updated financial expectations for the year ending December 31, 2025. Copies of the related press release and the investor presentation to be displayed during the Company's conference call on October 28, 2025 discussing such financial results and updated financial expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.** 

(d) Exhibits

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [<u>Press release issued by Alkermes plc on October 28, 2025 announcing financial results for the three and nine months ended September 30, 2025 and updating financial expectations for the year ending December 31, 2025.</u>](alks-ex99_1.htm) |
| 99.2 | [<u>Investor presentation to be displayed by Alkermes plc on October 28, 2025.</u>](alks-ex99_2.htm) |
| 104 | Cover page interactive data file (embedded within the Inline XBRL document). |

---

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ALKERMES PLC** | **ALKERMES PLC** |
| Date: October 28, 2025 | By: | /s/ Joshua Reed |
|  |  | Joshua Reed |
|  |  | Senior Vice President, Chief Financial Officer (Principal Financial Officer) |

---

------

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| &nbsp;&nbsp;<u>Alkermes Contacts:</u> |  |
| &nbsp;&nbsp;For Investors: | &nbsp;&nbsp;Sandy Coombs +1 781 609 6377 |
| &nbsp;&nbsp;For Media:  | &nbsp;&nbsp;Katie Joyce +1 781 249 8927 |

---

**Alkermes plc Reports Third Quarter 2025 Financial Results** 

*— Third Quarter Revenues of $394.2 Million —*

*— GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 —*

*— Company Raises 2025 Financial Expectations —*

**DUBLIN, Oct. 28, 2025 —** <u>Alkermes plc</u> (Nasdaq: ALKS) today reported financial results for the third quarter of 2025.

"Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals announced last week represents another potential growth driver for our business and an important element of our strategic plan as we seek to become a leader in the treatment of central disorders of hypersomnolence," said Richard Pops, Chief Executive Officer of Alkermes. "During the quarter, we also advanced our development pipeline, with notable progress in our orexin 2 receptor agonist program. We recently presented positive data from Vibrance-1, our phase 2 study of alixorexton in patients with narcolepsy type 1, and expect to report topline results from Vibrance-2, in narcolepsy type 2, next month. As we prepare to initiate our phase 3 clinical program in early 2026, we believe alixorexton represents a compelling opportunity to create value and deliver meaningful innovation to patients."

**<u>Key Financial Highlights</u>**

**Revenues**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;Total Revenues | $&nbsp;&nbsp;394.2 | $&nbsp;&nbsp;378.1 | $&nbsp;&nbsp;1091.4 | $&nbsp;&nbsp;1127.6 |
| &nbsp;&nbsp;Total Proprietary Net Sales | $&nbsp;&nbsp;317.4 | $&nbsp;&nbsp;273.0 | $&nbsp;&nbsp;869.2 | $&nbsp;&nbsp;775.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; VIVITROL<sup>®</sup> | $&nbsp;&nbsp;121.1 | $&nbsp;&nbsp;113.7 | $&nbsp;&nbsp;343.8 | $&nbsp;&nbsp;323.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ARISTADA<sup>®</sup><sup>i</sup> | $&nbsp;&nbsp;98.1 | $&nbsp;&nbsp;84.7 | $&nbsp;&nbsp;272.8 | $&nbsp;&nbsp;249.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYBALVI<sup>®</sup> | $&nbsp;&nbsp;98.2 | $&nbsp;&nbsp;74.7 | $&nbsp;&nbsp;252.6 | $&nbsp;&nbsp;203.1 |

---

**Profitability** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;GAAP Net Income From Continuing Operations | $&nbsp;&nbsp;82.8 | $&nbsp;&nbsp;92.8 | $&nbsp;&nbsp;192.3 | $&nbsp;&nbsp;226.4 |
| &nbsp;&nbsp;*GAAP Net Income (Loss) From Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(0.4)* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(5.8)* |
| &nbsp;&nbsp;GAAP Net Income  | $&nbsp;&nbsp;82.8 | $&nbsp;&nbsp;92.4 | $&nbsp;&nbsp;192.3 | $&nbsp;&nbsp;220.6 |
| &nbsp;&nbsp;EBITDA From Continuing Operations | $&nbsp;&nbsp;96.9 | $&nbsp;&nbsp;112.3 | $&nbsp;&nbsp;221.2 | $&nbsp;&nbsp;282.4 |
| &nbsp;&nbsp;*EBITDA From Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(0.5)* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*(6.9)* |
| &nbsp;&nbsp;EBITDA | $&nbsp;&nbsp;96.9 | $&nbsp;&nbsp;111.8 | $&nbsp;&nbsp;221.2 | $&nbsp;&nbsp;275.5 |
| &nbsp;&nbsp;Adjusted EBITDA | $&nbsp;&nbsp;121.5 | $&nbsp;&nbsp;134.3 | $&nbsp;&nbsp;293.7 | $&nbsp;&nbsp;351.4 |

---

------

**<u>Revenue Highlights</u>**

**LYBALVI**

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $98.2 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues and total prescriptions for the quarter grew 32% and 25%, respectively, compared to the third quarter of 2024.

**ARISTADA**<sup>i</sup>

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $98.1 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter grew 16% compared to the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;•During the quarter, the company recorded ARISTADA revenue of approximately $5.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.

**VIVITROL**

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter were $121.1 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the quarter grew 7% compared to the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;•During the quarter, the company recorded VIVITROL revenue of approximately $8.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.

**Manufacturing & Royalty Revenues**

&nbsp;&nbsp;&nbsp;&nbsp;•VUMERITY<sup>®</sup> manufacturing and royalty revenues for the quarter were $35.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;•Royalty revenues from XEPLION<sup>®</sup>, INVEGA TRINZA<sup>®</sup>/TREVICTA<sup>®</sup> and INVEGA HAFYERA<sup>®</sup>/BYANNLI<sup>®</sup> for the quarter were $30.2 million.

**<u>Key Operating Expenses</u>**

Please see Note 1 below for details regarding discontinued operations.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Three Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** | &nbsp;&nbsp;**Nine Months Ended** <br>**September 30,** |
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** |
| &nbsp;&nbsp;R&D Expense – Continuing Operations | $&nbsp;&nbsp;81.7 | $&nbsp;&nbsp;59.9 | $&nbsp;&nbsp;230.9 | $&nbsp;&nbsp;187.2 |
| &nbsp;&nbsp;*R&D Expense – Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*0.5* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;*6.9* |
| &nbsp;&nbsp;SG&A Expense – Continuing Operations | $&nbsp;&nbsp;171.8 | $&nbsp;&nbsp;150.4 | $&nbsp;&nbsp;514.3 | $&nbsp;&nbsp;498.2 |
| &nbsp;&nbsp;*SG&A Expense – Discontinued Operations* | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— | $&nbsp;&nbsp;— |

---

**<u>Balance Sheet</u>**

At Sept. 30, 2025, the company recorded cash, cash equivalents and total investments of $1.14 billion, compared to $1.05 billion at June 30, 2025.

------

**<u>Financial Expectations for 2025</u>**

Today, Alkermes raised its financial expectations for 2025, as set forth below. All line items are according to GAAP, except as otherwise noted.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;*(In millions)*  | &nbsp;&nbsp;**Previous 2025 Expectations**<br>**(provided Feb. 12, 2025)** | &nbsp;&nbsp;**Updated 2025 Expectations**<br>**(provided Oct. 28, 2025)** |
| &nbsp;&nbsp;Total Revenues  | &nbsp;&nbsp;$1340 – $1430 | &nbsp;&nbsp;$1430 – $1490 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VIVITROL Net Sales | &nbsp;&nbsp;$440 – $460 | &nbsp;&nbsp;$460 – $470 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ARISTADA<sup>i</sup> Net Sales | &nbsp;&nbsp;$335 – $355 | &nbsp;&nbsp;$360 – $370 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LYBALVI Net Sales | &nbsp;&nbsp;$320 – $340 | &nbsp;&nbsp;$340 – $350 |
| &nbsp;&nbsp;Cost of Goods Sold | &nbsp;&nbsp;$185 – $205 | &nbsp;&nbsp;$195 – $205 |
| &nbsp;&nbsp;R&D Expense | &nbsp;&nbsp;$305 – $335 | &nbsp;&nbsp;$315 – $325 |
| &nbsp;&nbsp;SG&A Expense | &nbsp;&nbsp;$655 – $685 | &nbsp;&nbsp;$675 – $705 |
| &nbsp;&nbsp;GAAP Net Income <sup>a</sup> | &nbsp;&nbsp;$175 – $205 | &nbsp;&nbsp;$230 – $250 |
| &nbsp;&nbsp;EBITDA <sup>b</sup> | &nbsp;&nbsp;$215 – $245 | &nbsp;&nbsp;$270 – $290 |
| &nbsp;&nbsp;Adjusted EBITDA <sup>b</sup> | &nbsp;&nbsp; $310 – $340  | &nbsp;&nbsp;$365 – $385  |
| &nbsp;&nbsp;Effective Tax Rate | &nbsp;&nbsp;~17% | &nbsp;&nbsp;~17% |

---

<sup>a</sup><sup></sup> Expected 2025 weighted average basic share count of approximately 165.5 million shares outstanding and a weighted average diluted share count of approximately 169.5 million shares outstanding <br> <sup>b</sup> Non-GAAP measure

**<u>Notes and Explanations</u>**

1. The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, *Discontinued Operations*. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and nine months ended Sept. 30, 2024.

**<u>Conference Call</u>**

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.

**<u>About Alkermes plc</u>**

Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

**<u>Non-GAAP Financial Measures</u>**

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

------

EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings.

The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

**<u>Note Regarding Forward-Looking Statements</u>**

Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects; the company's expectations related to its proposed acquisition of Avadel Pharmaceuticals; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, alixorexton. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be initiated or completed on expected timelines or at all; the results of the company's development activities may not be positive, or predictive of future results from such activities, results of future development activities or real-world results; the company's products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or may make adverse decisions regarding the company's products; potential changes in the cost, scope and duration of the company's development programs; whether the proposed acquisition will be consummated on the anticipated terms, timelines or at all; even if the proposed acquisition is consummated, the expected benefits of the proposed acquisition may not be achieved; there may be significant changes in transaction costs and/or unknown or inestimable liabilities and potential litigation associated with the proposed acquisition; the unfavorable outcome of arbitration, litigation, including so-called "Paragraph IV" litigation and other patent litigation which may lead to competition from generic manufacturers, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

------

VIVITROL<sup>®</sup> is a registered trademark of Alkermes, Inc.; ARISTADA<sup>®</sup>, ARISTADA INITIO<sup>®</sup> and LYBALVI<sup>®</sup> are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI<sup>®</sup>, INVEGA HAFYERA<sup>®</sup>, INVEGA TRINZA<sup>®</sup>, TREVICTA<sup>®</sup> and XEPLION<sup>®</sup> are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY<sup>®</sup> is a registered trademark of Biogen MA Inc., used by Alkermes under license.

(tables follow)

<sup>i</sup> The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO<sup>®</sup>, unless the context indicates otherwise.

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Statements of Operations - GAAP** | **Three Months Ended** | **Three Months Ended** |
| **(In thousands, except per share data)** | **September 30, 2025** | **September 30, 2024** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;Product sales, net | $317423 | $272999 |
| &nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | 76762 | 105144 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Revenues | 394185 | 378143 |
| Expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold | 51591 | 63099 |
| &nbsp;&nbsp;&nbsp;Research and development | 81739 | 59892 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 171773 | 150382 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets |  | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Expenses | 305103 | 273387 |
| Operating Income | 89082 | 104756 |
| Other Income, net: |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 11943 | 10916 |
| &nbsp;&nbsp;&nbsp;Interest expense |  | (6000) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | (280) | 558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Income, net | 11663 | 5474 |
| Income Before Income Taxes | 100745 | 110230 |
| Income Tax Provision | 17984 | 17435 |
| **Net Income From Continuing Operations** | 82761 | 92795 |
| **Loss From Discontinued Operations — Net of Tax** |  | (414) |
| **Net Income — GAAP** | $82761 | $92381 |
| **GAAP Earnings (Loss) Per Ordinary Share - Basic:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.50 | $0.57 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.00) |
| &nbsp;&nbsp;From net income | $0.50 | $0.57 |
| **GAAP Earnings (Loss) Per Ordinary Share - Diluted:** |  |  |
| &nbsp;&nbsp;From continuing operations | $0.49 | $0.56 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.00) |
| &nbsp;&nbsp;From net income | $0.49 | $0.55 |
| **Weighted Average Number of Ordinary Shares Outstanding:** |  |  |
| &nbsp;&nbsp;Basic | 165086 | 163368 |
| &nbsp;&nbsp;Diluted | 168510 | 167025 |

---

------

---

| | | |
|:---|:---|:---|
| **Condensed Consolidated Statements of Operations - GAAP (Continued)**<br>**(In thousands, except per share data)** | **Three Months Ended**<br>**September 30, 2025** | **Three Months Ended**<br>**September 30, 2024** |
| An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: |  |  |
| **Net Income from Continuing Operations** | $82761 | $92795 |
| Adjustments: |  |  |
| &nbsp;&nbsp;Depreciation expense | 8060 | 6958 |
| &nbsp;&nbsp;Amortization expense | 19 | 14 |
| &nbsp;&nbsp;Interest income | (11943) | (10916) |
| &nbsp;&nbsp;Interest expense |  | 6000 |
| &nbsp;&nbsp;Income tax provision | 17984 | 17435 |
| **EBITDA from Continuing Operations** | 96881 | 112286 |
| **EBITDA from Discontinued Operations** |  | (481) |
| **EBITDA** | $96881 | $111805 |
| &nbsp;&nbsp;Share-based compensation | 24665 | 22533 |
| **Adjusted EBITDA** | $121546 | $134338 |

---

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Statements of Operations - GAAP** | **Nine Months Ended** | **Nine Months Ended** |
| **(In thousands, except per share data)** | **September 30, 2025** | **September 30, 2024** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;Product sales, net | $869151 | $775808 |
| &nbsp;&nbsp;&nbsp;Manufacturing and royalty revenues | 222201 | 351835 |
| &nbsp;&nbsp;&nbsp;Research and development revenue |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Revenues | 1091352 | 1127646 |
| Expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Cost of goods manufactured and sold | 150248 | 183215 |
| &nbsp;&nbsp;&nbsp;Research and development | 230926 | 187152 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 514326 | 498244 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets |  | 1087 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Expenses | 895500 | 869698 |
| Operating Income | 195852 | 257948 |
| Other Income, net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 33174 | 31050 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense |  | (17930) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 2047 | 2793 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Income, net | 35221 | 15913 |
| Income Before Income Taxes | 231073 | 273861 |
| Income Tax Provision | 38750 | 47460 |
| **Net Income From Continuing Operations** | 192323 | 226401 |
| **Loss From Discontinued Operations — Net of Tax** |  | (5834) |
| **Net Income — GAAP** | $192323 | $220567 |
| **GAAP Earnings (Loss) Per Ordinary Share - Basic:** |  |  |
| &nbsp;&nbsp;From continuing operations | $1.17 | $1.36 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.04) |
| &nbsp;&nbsp;From net income | $1.17 | $1.32 |
| **GAAP Earnings (Loss) Per Ordinary Share - Diluted:** |  |  |
| &nbsp;&nbsp;From continuing operations | $1.14 | $1.33 |
| &nbsp;&nbsp;From discontinued operations | $— | $(0.03) |
| &nbsp;&nbsp;From net income | $1.14 | $1.30 |
| **Weighted Average Number of Ordinary Shares Outstanding:** |  |  |
| &nbsp;&nbsp;Basic | 164490 | 166546 |
| &nbsp;&nbsp;Diluted | 168445 | 170196 |

---

------

---

| | | |
|:---|:---|:---|
| **Condensed Consolidated Statements of Operations - GAAP (Continued)**<br>**(In thousands, except per share data)** | **Nine Months Ended**<br>**September 30, 2025** | **Nine Months Ended**<br>**September 30, 2024** |
| An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows: |  |  |
| **Net Income from Continuing Operations** | $192323 | $226401 |
| Adjustments: |  |  |
| &nbsp;&nbsp;Depreciation expense | 23262 | 20599 |
| &nbsp;&nbsp;Amortization expense | 56 | 1087 |
| &nbsp;&nbsp;Interest income | (33174) | (31050) |
| &nbsp;&nbsp;Interest expense |  | 17930 |
| &nbsp;&nbsp;Income tax provision | 38750 | 47460 |
| **EBITDA from Continuing Operations** | 221217 | 282427 |
| **EBITDA from Discontinued Operations** |  | (6910) |
| **EBITDA** | $221217 | $275517 |
| &nbsp;&nbsp;Share-based compensation | 72441 | 75889 |
| **Adjusted EBITDA** | $293658 | $351406 |

---

------

---

| | | |
|:---|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** | **Selected Financial Information (Unaudited)** |
| **Condensed Consolidated Balance Sheets** | **September 30,** | **December 31,** |
| **(In thousands)** | **2025** | **2024** |
| Cash, cash equivalents and total investments | $1138983 | $824816 |
| Receivables | 354394 | 384528 |
| Inventory | 190997 | 182887 |
| Contract assets | 717 | 4990 |
| Prepaid expenses and other current assets | 84442 | 91282 |
| Property, plant and equipment, net | 246982 | 227564 |
| Intangible assets, net and goodwill | 83861 | 83917 |
| Deferred tax assets | 130344 | 154835 |
| Other assets | 98792 | 100748 |
| &nbsp;&nbsp;&nbsp;**Total Assets** | $2329512 | $2055567 |
| Accrued sales discounts, allowances and reserves | $252743 | $272452 |
| Other current liabilities | 221617 | 192747 |
| Other long-term liabilities | 121720 | 125391 |
| Total shareholders' equity | 1733432 | 1464977 |
| &nbsp;&nbsp;&nbsp;**Total Liabilities and Shareholders' Equity** | $2329512 | $2055567 |
| Ordinary shares outstanding (in thousands) | 165104 | 162177 |
| This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which the company intends to file in October 2025. | This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which the company intends to file in October 2025. | This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which the company intends to file in October 2025. |

---

------

---

| | |
|:---|:---|
| **Alkermes plc and Subsidiaries** | **Alkermes plc and Subsidiaries** |
| **2025 Guidance — GAAP to EBITDA** | **2025 Guidance — GAAP to EBITDA** |
| An itemized reconciliation between projected net income on a GAAP basis, EBITDA and Adjusted EBITDA is as follows: | An itemized reconciliation between projected net income on a GAAP basis, EBITDA and Adjusted EBITDA is as follows: |
| **(In millions)** | **Amount** |
| Projected Net Income — GAAP | $240.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments: |  |
| &nbsp;&nbsp;&nbsp;Interest income | (40.0) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 30.0 |
| &nbsp;&nbsp;&nbsp;Provision for income taxes | 50.0 |
| Projected EBITDA | $280.0 |
| &nbsp;&nbsp;Share-based compensation expense | 95.0 |
| Projected Adjusted EBITDA | $375.0 |
| Projected Net Income on a GAAP basis and Projected EBITDA and Adjusted EBITDA reflect mid-points within ranges of estimated guidance. | Projected Net Income on a GAAP basis and Projected EBITDA and Adjusted EBITDA reflect mid-points within ranges of estimated guidance. |

---

------

## Exhibit 99.2

![Slide 1](alks-ex99_2s1.jpg)

Third Quarter 2025Financial Results & Business Update October 28, 2025 Exhibit 99.2

------

![Slide 2](alks-ex99_2s2.jpg)

Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or prospects, including its expected revenue and profitability. The Company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks, assumptions and uncertainties. These risks, assumptions and uncertainties include, among others: whether the Company is able to achieve its financial expectations; the Company's commercial activities may not result in the benefits that the Company anticipates; clinical development activities may not be initiated or completed on expected timelines or at all; the results of the Company's development activities may not be positive, or predictive of future results from such activities, results of future development activities or real-world results; the Company's products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may not agree with the Company's regulatory approval strategies or may make adverse decisions regarding the Company's products; potential changes in the cost, scope, design or duration of the Company's development programs; the unfavorable outcome of arbitration, litigation, including so-called "Paragraph IV" litigation and other patent litigation which may lead to competition from generic manufacturers, or other proceedings or disputes related to the Company's products or products using the Company's proprietary technologies; the Company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the Company's products or an increase in the Company's financial obligations to government payers; the Company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks, assumptions and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the Company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov, and on the Company's website at www.alkermes.com in the 'Investors – SEC Filings' section. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. Non-GAAP Financial Measures: This presentation includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. ("GAAP"), including EBITDA (earnings before interest, taxes, depreciation and amortization) and Adjusted EBITDA, which excludes from earnings share-based compensation expense in addition to the components of EBITDA. The Company provides these non-GAAP financial measures of the Company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures, to the extent reasonably determinable, can be found in the Appendix of this presentation. Note Regarding Trademarks: The Company and its affiliates are the owners of various U.S. federal trademark registrations (®) and other trademarks (TM), including ARISTADA®, ARISTADA INITIO® , LYBALVI® and VIVITROL®. INVEGA SUSTENNA® is a registered trademark of Johnson & Johnson or its affiliated companies. Any other trademarks referred to in this presentation are the property of their respective owners. Appearances of such other trademarks herein should not be construed as any indicator that their respective owners will not assert their rights thereto.

------

![Slide 3](alks-ex99_2s3.jpg)

Q3 2025 Financial and Operational Performance

------

![Slide 4](alks-ex99_2s4.jpg)

In millions Q3 2025 Financial Results Summary Total Revenue In millions GAAP Net Income GAAP Earnings Per Share Diluted Q3 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024.

------

![Slide 5](alks-ex99_2s5.jpg)

In millions Q3 2025 Profitability GAAP Net Income From Continuing Operations In millions Adjusted EBITDA\* EBITDA\* From Continuing Operations In millions EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes from earnings share-based compensation expense in addition to the components of EBITDA.\*Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. Q3 2025 results reflect expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024.

------

![Slide 6](alks-ex99_2s6.jpg)

Q3 2025 Revenue Summary In millions Q3'25 Q3'24 Total Proprietary Net Sales $317.4 $273.0 VIVITROL® $121.1 $113.7 ARISTADA®\* $98.1 $84.7 LYBALVI® $98.2 $74.7 Manufacturing & Royalty Revenue $76.8 $105.1 Total Revenue $394.2 $378.1 \*Inclusive of ARISTADA INITIO®. \*\*Reflects expiration of royalty on U.S. net sales of INVEGA SUSTENNA® in August 2024. \*\* \*\* Amounts in the table may not sum due to rounding. \*\* \*\*

------

![Slide 7](alks-ex99_2s7.jpg)

Alkermes: 2025 Financial Expectations \*These expectations are provided by the Company on Oct. 28, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. ‡Reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the Appendix of this presentation. i Inclusive of ARISTADA INITIO®. (in millions) Previous Financial Expectations for Year Ending Dec. 31, 2025 (provided Feb. 12, 2025) Updated Financial Expectations for Year Ending Dec. 31, 2025\* (provided Oct. 28, 2025) Total Revenues $1,340 – $1,430 $1,430 – $1,490 COGS $185 – $205 $195 – $205 R&D Expense $305 – $335 $315 – $325 SG&A Expense $655 – $685 $675 – $705 GAAP Net Income $175 – $205 $230 – $250 EBITDA‡ $215 – $245 $270 – $290 Adjusted EBITDA‡ $310 – $340 $365 – $385 Effective Tax Rate ~17% ~17% Expected net sales of proprietary products for year ending Dec. 31, 2025\*: VIVITROL® net sales of $460M – $470M ARISTADA®i net sales of $360M – $370M LYBALVI® net sales of $340M – $350M EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes from earnings share-based compensation expense in addition to the components of EBITDA.

------

![Slide 8](alks-ex99_2s8.jpg)

Q3 2025 Commercial Review

------

![Slide 9](alks-ex99_2s9.jpg)

LYBALVI® Performance and Expectations \*These expectations are provided by the Company on Oct. 28, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. LYBALVI Quarterly Net Sales ($M) Q3'25 LYBALVI net sales of $98.2M reflects 32% growth compared to Q3'24 Q3'25 gross-to-net deductions: ~28% Outlook: FY'25 net sales expected to range from $340M – $350M\*

------

![Slide 10](alks-ex99_2s10.jpg)

ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales\* ($M) Q3'25 ARISTADA net sales were $98.1M Outlook: FY'25 net sales expected to range from $360M – $370M†\* \*Inclusive of ARISTADA INITIO®.†These expectations are provided by the Company on Oct. 28, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations.

------

![Slide 11](alks-ex99_2s11.jpg)

VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) \*These expectations are provided by the Company on Oct. 28, 2025 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q3'25 VIVITROL net sales were $121.1M Outlook: FY'25 net sales expected to range from $460M – $470M\*

------

![Slide 12](alks-ex99_2s12.jpg)

Appendix

------

![Slide 13](alks-ex99_2s13.jpg)

Appendix: Amounts Included in Discontinued Operations (In thousands) Year Ended December 31, 2023 Three Months Ended September 30, 2024 Cost of goods manufactured and sold $-- Research and development 481 Selling, general and administrative --- Income tax benefit $(67) Loss from discontinued operations, net of tax $414

------

![Slide 14](alks-ex99_2s14.jpg)

Appendix: Financial Results GAAP to Non-GAAP Reconciliation (In millions) Three Months Ended September 30, 2025 Three Months Ended September 30, 2024 Net Income from Continuing Operations — GAAP $82.8 $92.8 Adjustments: Depreciation expense 8.1 7.0 Amortization expense 0.0 0.0 Interest income (11.9) (10.9) Interest expense -- 6.0 Income tax provision 18.0 17.4 EBITDA from Continuing Operations 96.9 112.3 EBITDA from Discontinued Operations -- (0.5) EBITDA 96.9 111.8 Share-based compensation 24.7 22.5 Adjusted EBITDA $121.5 $134.3 Amounts in the table may not sum due to rounding.

------

![Slide 15](alks-ex99_2s15.jpg)

Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Projected GAAP and non-GAAP measures in the table above reflect the mid-points within the Company's financial expectations ranges. (In millions) Year Ended December 31, 2023 Year Ending December 31, 2025 Projected Net Income — GAAP $240.0 Adjustments: Interest income (40.0) Depreciation and amortization expense 30.0 Provision for income taxes 50.0 Projected EBTIDA $280.0 Shared-based compensation expense 95.0 Projected Adjusted EBITDA $375.0

------

![Slide 16](alks-ex99_2s16.jpg)

www.alkermes.com